1. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. (May 2013) Authors: Thariani, Rahber; Henry, Norah Lynn; Ramsey, Scott D; Blough, David K; Barlow, Bill; Gralow, Julie R; Veenstra, David L Journal: Journal of comparative effectiveness research Issue: Volume 2:Number 3(2013) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. (6th December 2018) Authors: Marcath, Lauren A; Kidwell, Kelley M; Robinson, Adam C; Vangipuram, Kiran; Burness, Monika L; Griggs, Jennifer J; Poznak, Catherine Van; Schott, Anne F; Hayes, Daniel F; Henry, Norah Lynn; Hertz, Daniel L Journal: Pharmacogenomics Issue: Volume 20:Number 2(2019) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Socioeconomic deprivation and patient-reported outcomes in symptom management trials for patients with breast cancer. Issue 28 (1st October 2022) Authors: Vaidya, Riha; Till, Cathee; Henry, Norah Lynn; Fisch, Michael Jordan; Hershman, Dawn L.; Unger, Joseph M. Journal: Journal of clinical oncology Issue: Volume 40:Issue 28(2022)Supplement Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗